May 6, 2008
Submitted by art on Wed, 2008-05-07 06:44.
MediciNova has announced positive clinical findings from the completed two-year Phase II clinical trial of orally administered MN-166 for the treatment of multiple sclerosis.
The data showed that sustained disability progression was significantly less likely (by approximately 50%) in those patients receiving MN-166 at either 30 or 60mg per day for 24 months than in those patients receiving the drug for 12 months (p=0.026).